KRAS and neoplasm: Recent data from combinatorial treatment with AMG510 and anti–PD-1 immunotherapy increased survival of mice, and 90% of mice responded to therapy with complete tumor regression, suggesting that the efficiency of classical immunotherapies can be augmented as a result of the unleashing of antitumor immunity when oncogenic KRAS or downstream signaling pathways are inhibited (22).